Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Seagen Inc. Market Cap
From what 0 stock analysts predict, the share price for Seagen Inc. (SGEN) might decrease by 100% in the next year. This is based on a 12-month average estimation for SGEN. Price targets go from $ to $. The majority of stock analysts believe SGEN is a sell. Please note analyst price targets are not guaranteed and could be missed completely.
About 0 Wall Street analysts have assigned SGEN 0 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Seagen Inc. to perform worse than the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on SGEN. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| jay olson Oppenheimer | Buy | $229.0 | maintained | Nov 7, 2023 |
| boris peaker TD Cowen | Hold | $229.0 | maintained | Nov 1, 2023 |
| kaveri pohlman BTIG | Hold | None | rated | Nov 1, 2023 |
| andrew berens Leerink Partners | Hold | $229.0 | reiterated | Nov 1, 2023 |
| etzer darout BMO Capital | Hold | $229.0 | maintained | Nov 1, 2023 |
| gregory renza RBC Capital | Buy | $229.0 | maintained | Nov 1, 2023 |
| salveen richter Goldman Sachs | Buy | None | maintained | Nov 1, 2023 |
| reni benjamin JMP Securities | Hold | None | maintained | Aug 4, 2023 |
| terence flynn Morgan Stanley | Hold | $229.0 | maintained | Aug 3, 2023 |
| joseph catanzaro Piper Sandler | Hold | $229.0 | rated | Jun 6, 2023 |
| zhiqiang shu Berenberg Bank | Hold | $229.0 | maintained | May 16, 2023 |
| stephen willey Stifel Nicolaus | Hold | $229.0 | maintained | May 1, 2023 |
| matthew harrison Morgan Stanley | Hold | $229.0 | maintained | Apr 3, 2023 |
| asthika goonewardene Truist Financial | Hold | $229.0 | maintained | Mar 20, 2023 |
| ami fadia Needham | Hold | None | downgraded | Mar 13, 2023 |
| dane leone Raymond James | Hold | None | downgraded | Mar 13, 2023 |
| joshua schimmer Evercore ISI | Hold | $229.0 | downgraded | Mar 13, 2023 |
| michael schmidt Guggenheim | Buy | $170.0 | reiterated | Feb 28, 2023 |
| andrew fein H.C. Wainwright | Buy | $180.0 | reiterated | Feb 16, 2023 |
| jessica fye J.P. Morgan | Buy | $153.0 | maintained | Feb 16, 2023 |
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington. As of December 14, 2023, Seagen Inc. operates as a subsidiary of Pfizer Inc.
When did it IPO
2001
Staff Count
3,256
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. David R. Epstein B.Sc., M.B.A.
Market Cap
$700.22B
In 2023, SGEN generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that SGEN's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2019
Revenue From 2020
Revenue From 2021
Revenue From 2022
TSLA-USD
$193.76
COST-USD
$723.02
$181.86
ADBE-USD
$537.57
PEP-USD
$166.32
CSCO-USD
$48.48
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
